13F Holdings
中文EN

DGX QUEST DIAGNOSTICS INC

Services-Medical Laboratories · NYSE · SEC CIK 1022079 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY9.1%
TTM net income YoY16.5%
TTM EPS YoY17.8%
Revenue 3-yr CAGR8.4%
Net income 3-yr CAGR14.0%

Margins

Gross margin33.1%
Operating margin14.6%
Net margin9.5%
FCF margin11.6%
EBITDA margin19.5%

Returns

ROE15.2%
ROA6.8%
ROIC (approx.)10.7%
Asset turnover0.71x

Leverage & solvency

Liabilities / assets53.4%
Debt / equity0.73x
Current ratio1.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.73x
Accruals ratio-4.9%
Payout ratio32.7%
Capex / revenue4.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$11.04B$9.87B$9.25B$9.88B$10.79B
Cost of revenue$7.37B$6.63B$6.20B$6.45B$6.58B
Gross profit$3.67B$3.24B$3.05B$3.43B$4.21B
SG&A expense$1.97B$1.77B$1.64B$1.87B$1.73B
Operating income$1.56B$1.35B$1.26B$1.43B$2.38B
Interest expense——$163.00M$148.00M$152.00M
Pretax income$1.32B$1.18B$1.13B$1.24B$2.60B
Income tax$314.00M$273.00M$248.00M$264.00M$597.00M
Net income$992.00M$871.00M$854.00M$946.00M$2.00B
EBITDA$2.13B$1.84B$1.70B$1.86B$2.79B
EPS (basic)8.877.787.598.1015.85
EPS (diluted)8.757.697.497.9715.55
Weighted avg. shares (diluted)113.00M113.00M113.00M118.00M128.00M
Banking
Net interest income-$264.00M-$201.00M-$152.00M-$138.00M-$151.00M
Balance sheet
Cash & equivalents$420.00M$549.00M$686.00M$315.00M$872.00M
Receivables$1.41B$1.30B$1.21B$1.20B$1.44B
Inventory$189.00M$188.00M$190.00M$192.00M$208.00M
Current assets$2.38B$2.39B$2.37B$1.90B$2.74B
PP&E, net$2.20B$2.11B$1.82B$1.77B$1.71B
Goodwill$8.95B$8.86B$7.73B$7.22B$7.09B
Intangibles$1.64B$1.76B$1.17B$1.09B$1.17B
Total assets$16.23B$16.15B$14.02B$12.84B$13.61B
Current liabilities$2.28B$2.17B$1.81B$1.55B$1.75B
Short-term debt$504.00M$602.00M$303.00M$2.00M$2.00M
Long-term debt$5.17B$5.62B$4.41B$3.98B$4.01B
Total debt$5.67B$6.22B$4.71B$3.98B$4.01B
Total liabilities$8.94B$9.26B$7.60B$6.83B$7.05B
Shareholders' equity$7.17B$6.78B$6.31B$5.89B$6.44B
Net debt$5.25B$5.67B$4.03B$3.67B$3.14B
Cash flow statement
Operating cash flow$1.89B$1.33B$1.27B$1.72B$2.23B
Capital expenditure$527.00M$425.00M$408.00M$404.00M$403.00M
Free cash flow$1.36B$909.00M$864.00M$1.31B$1.83B
Investing cash flow-$631.00M-$2.55B-$1.06B-$543.00M$21.00M
Financing cash flow-$1.39B$1.08B$160.00M-$1.73B-$2.54B
Depreciation & amortization$570.00M$493.00M$439.00M$437.00M$408.00M
Stock-based compensation$88.00M$88.00M$77.00M$77.00M$79.00M
Dividends paid$353.00M$331.00M$314.00M$305.00M$309.00M
Share buybacks$450.00M$151.00M$275.00M$1.41B$2.20B

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.